The safety of moxidectin 1% injectable anthelmintic (0.6 mg/kg of body weight, 3 times the recommended dose) was evaluated in 145 reproductively sound, beef cows undergoing estrous cycle. Five treatment groups received moxidectin 1% injectable at specific times relative to a synchronized estrus (day 0): preovulatory treatment (day -2, treatment group 1), treatment at ovulation (day 0, group 2), and treatment after ovulation (days 7, 14, and 28, group 3, 4, and 5, respectively). Two groups of control cows received an injection of vehicle only at times corresponding to treatment in the other groups (6 at days -2, 7, and 28; 7 at days 0, 7, and 14). A final control group (8) received neither product or vehicle. Adverse clinical reactions were not observed in moxidectin- or vehicle-treated cows. Cows were bred by artificial insemination between days -2 and 25 and, subsequently, by breeding-sound bulls through day 65 of the study. Treatment and control groups did not differ in pregnancy rate or time to conception. Moxidectin (at 3 times the therapeutic dose) did not have deleterious effects on cow reproductive performance as examined (eg, at folliculogenesis, ovulation, and the early embryonic phase of development).

The left ovary of chicken embryos was removed and incubated in culture medium with a thymidine analogue, bromodeoxyuridine (BrdU), in vitro. In addition, fertile chicken eggs were injected with BrdU via the extraembryonic vessels and incubated for 24 hours. The ovaries were then processed for immunohistochemical localization of calbindin-D28K (a 28-kd vitamin D-dependent calcium-binding protein) and BrdU. Calbindin-D28K was detected in the germinal epithelium and in cells surrounding the oogonia and oocytes (future granulosa cells) of the embryonic chicken ovary. However, Brdu was observed in the nucleus of the oogonia and oocytes of the chicken embryonic ovaries. Comparison of the 2 adjacent sections, immunostained for calbindin-D28K and BrdU consecutively, indicated that BrdU, the marker for cell proliferation was not detected in calbindin-D28K-containing cells, namely, germinal epithelium and future granulosa cells, in the ovary of chicken embryos. These results suggested that calbindin-D28K-containing cells in the ovary were not in the process of cell division during the 24-hour incubation of chicken embryos.

Immunoreactivity for 28 kd vitamin D-dependent calcium-binding protein (calbindin-D28k) has been localized in the germinal epithelium and cells surrounding oogonia and oocytes (future granulosa cells) of developing and growing ovaries of chicken embryos. The protein first appeared prominently in the germinal epithelium of the developing left ovary in 8-day embryos. At the twelfth day of incubation, cells surrounding oogonia and oocytes reacted intensely for calbindin-D28k. The number and intensity of calbindin-D28k-containing cells increased in both types of cells as the embryos further developed. Calbindin-D28k remained in the germinal epithelium throughout the study period observed (up to 10 weeks). However, the protein was present transiently in the future granulosa cells. It gradually decreased after hatching, and was virtually absent from granulosa cells in a 10-week old chicken. Compared with the known process of onset of sexual development, these results indicated possible involvement of calbindin-D28k in the early phases of oogenesis in chicken ovaries.